COPD: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• NRF2 0
• MAPK 0
• NLRP3 0
• PI3K 0
• STAT3 0
• GLP-1 1
• SIRT1 0
• PDE4 0
• AKT 0
• ERK 0
• STING 0
• TP53 0
• TSLP 2
• JAK 0
• TLR4 0
• IL-6 2
• MMP-9 0
• mTOR 0
• PPAR 0
• CFTR 0
• GPX4 0
• IL-17 0
• PD-L1 1
• TNF 0
• VEGF 0
• AMPK 0
• HIF-1 0
• PD-1 0
• SGLT2 0
• EGFR 0
• JNK 0
• COX-2 0
• CTNNB1 0
• CXCR4 0
• HDAC 0
• IL-1 0
• BDNF 0
• BRD4 0
• CD40 0
• DPP-4 0
• FTO 0
• HER2 0
• HMGB1 0
• KRAS 0
• MDM2 0
• METTL3 0
• PTEN 0
• RANKL 0
• TIGIT 0
• YAP 0
• ABL1 0
• AQP4 0
• BCMA 0
• CD38 0
• CDKN2A 0
• FAK 0
• FGFR 0
• G6PD 0
• HTT 0
• IL-13 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Improve Muscle Weakness in Patient With COPD

  NCT07649850· Al-Zaytoonah University of Jordan· Updated 21 Oct 2026

  “no participant enrolled”Registry text, quoted unchanged. Source

• Terminated

  A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

  NCT06603246· Genentech, Inc.· Updated 20 Oct 2026

  “Sponsor's Decision”Registry text, quoted unchanged. Source

• Suspended

  Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

  NCT07541378· Medical University of Bialystok· Updated 2 Oct 2026

  “Recruitment was temporarily suspended pending additional funding and activation of additional study centers. The pilot phase has been completed and is currently being evaluated. The suspension was not related to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study

  NCT06735612· Fundacio Privada Mon Clinic Barcelona· Updated 14 Sept 2026

  “After extending RECODE recruitment for a second year due to low enrolment, the Sponsor closed it on 1 May 2026, after the second RSV season, with 716/892 patients. Further non-RSV recruitment offered limited value; there were no safety concerns.”Registry text, quoted unchanged. Source

• Suspended

  A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

  NCT07633314· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Updated 3 Sept 2026

  “The sponsor has decided to suspend study progress. Further implementation of the study is pending notification.”Registry text, quoted unchanged. Source

• Terminated

  Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstructive Pulmonary Disease

  NCT06118632· Chelsea and Westminster NHS Foundation Trust· Updated 11 Aug 2026

  “Sponsor decision due to data collection concerns”Registry text, quoted unchanged. Source

• Withdrawn

  Hypoxia and Heart Rate Variability

  NCT05606406· University of Miami· Updated 3 Aug 2026

  “Study stopped due to no recruitment activities”Registry text, quoted unchanged. Source

• Terminated

  CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

  NCT05546606· Assistance Publique - Hôpitaux de Paris· Updated 9 Jul 2026

  “Early termination due to industry withdrawal”Registry text, quoted unchanged. Source

• Withdrawn

  A COPD Data Registry for Participants With Frequent Exacerbations

  NCT07059273· Hoffmann-La Roche· Updated 22 Jun 2026

  “The study was withdrawn due to a business decision.”Registry text, quoted unchanged. Source

• Terminated

  Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients

  NCT03774238· University Hospital, Montpellier· Updated 12 Jun 2026

  “Analyses will be carried out with the recruited population.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

  NCT07874815· Merck Sharp & Dohme LLC· Source

• The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.

  NCT07923656· University Hospital, Bordeaux· Source

• Local Antibiotic Delivery for Community Acquired Pneumonia

  NCT06859450· Copenhagen Respiratory Research· Source

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· UCB Biopharma SRL· Source

• A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

  NCT06154837· GlaxoSmithKline· Source

• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

  NCT07780656· GlaxoSmithKline· Source

• A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Eli Lilly and Company· Source

• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

  NCT07780669· GlaxoSmithKline· Source

• Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

  NCT07051707· Nuvaira, Inc.· Source

• WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

  NCT07558265· Ohio State University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 7
• Mendelian Randomization Analysis 68
• CRISPR-Cas Systems 1
• Gene Expression Profiling 68
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Proteomics 31
• Metabolomics 34
• Mass Spectrometry 5
• Flow Cytometry 5
• Immunohistochemistry 5
• Liquid Biopsy 2
• Circulating Tumor DNA 1
• Magnetic Resonance Imaging 32
• Machine Learning 103
• Deep Learning 33
• Cohort Studies 225
• Genome-Wide Association Study 71

• Integrative Single-Cell and Bulk RNA Sequencing Analysis Identifies Ion Channel-Related Biomarkers in Chronic Obstructive Pulmonary Disease.

  Int J Chron Obstruct Pulmon Dis, Oct 2026

• Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.

  Transl Res, Jun 2026

• Modulation of Inflammatory and Oxidative Stress Pathways in COPD: Unraveling the Mechanisms of Fenugreek Through Network Pharmacology and Single-Cell RNA Sequencing.

  Int J Chron Obstruct Pulmon Dis, Mar 2026

• Single-Cell RNA Sequencing of Human Lung Tissues Reveals Metallothionein-Positive T Cells as a Novel Potential Marker of Susceptibility to Chronic Obstructive Pulmonary Disease.

  Adv Sci (Weinh), Feb 2026

• Single-cell RNA sequencing elucidates potential mechanisms of endothelial cells in lung region-specific repair and remodeling in combined pulmonary fibrosis and emphysema.

  Respir Res, Jan 2026

• Single-Cell RNA Analysis Reveals Aberrant Expression of Immune-Related Genes and Transcriptional Regulation of NK Cells in Chronic Obstructive Pulmonary Disease.

  Crit Rev Immunol, Jan 2025

• Vitamin D3-vitamin D receptor axis suppresses pulmonary emphysema by maintaining alveolar macrophage homeostasis and function.

  EBioMedicine, Jul 2019

See which targets of this disease your abstract mentions, and go to the people working on them.